Sponsored Content
U.S. Forest Laboratories Cooperates with Nabriva
The U.S. pharmaceutical company provides funds of $ 25m to the Austrian Nabriva and secures pre-emptory rights.
U.S. Forest Laboratories Cooperates with Nabriva / Picture: © Vindobona.org
Forest Laboratories and Nabriva Therapeutics announced today they have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Pursuant to the agreement, Forest will provide Nabriva with $ 25m, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months. During the 12-month…
or Log In
Fast News Search